| |
May 1 - 3, 2023 | Jersey City, NJ Don’t miss the opportunity to gain best practices in medical affairs strategy development and ensuring scientific materials are created and shared in a regulatory compliant manner to internal/external stakeholders and thought leaders. Take advantage of the Early Bird Rates,Register Today!
|
|
Today's Big NewsFeb 6, 2023 |
|
Tuesday, February 28, 2023 | 11am ET / 8am PT The heavy lifting for the pharmaceutical industry to comply with the November 2023 DSCSA go-live date is still ongoing. One item now finalized is to ensure that the required data exchange through the supply chain is only done with trusted, authorized, and registered trading partners. Join us for this discussion to stay up-to-date on this important legislation and be prepared for compliance. Register now.
|
|
| By Ben Adams,Zoey Becker,Kevin Dunleavy For the third year in a row, Evaluate Vantage’s most hotly tipped drug approval when it comes to future sales potential is an Alzheimer’s therapy, but there is far more caution in this year’s list than we have seen before. |
|
|
|
By Conor Hale,Andrea Park In 2021, light at the end of the COVID tunnel spurred an explosion of medtech deals. But in 2022, that exuberance waned. |
By James Waldron When Johnson & Johnson acquired nipocalimab as part of the $6.5 billion takeover of Momenta, the hype surrounding the therapy was focused on its potential as a treatment for the hot disease area of myasthenia gravis. But a top-line phase 2 readout for the drug in a fetal disorder is a reminder that nipocalimab could have a far broader reach. |
By Fraiser Kansteiner As Eisai focuses on laying the commercial groundwork for Leqembi ahead of a potential full approval, the company "will make every effort to support healthcare providers and patients for those who are able to access" the new Alzheimer's drug, Eisai's Ivan Cheung said Monday. |
|
Evidation and Fierce Biotech conducted a survey of industry professionals to gather insights on the role integrated evidence strategies play in their businesses, as well as the impact of these strategies in helping to deliver better health outcomes. Access the findings from this important survey now.
|
|
By Nick Paul Taylor Add Aug. 5 to your diaries. That is the FDA's decision date for Biogen and Sage Therapeutics' zuranolone, which the agency has accepted for priority review as an oral treatment of major depressive disorder and postpartum depression. |
By Zoey Becker Sanofi prides itself on Regeneron-partnered Dupixent and its flu vaccines. During the fourth quarter, Dupixent sales surged—as usual—but vaccine sales sank. |
By Andrea Park In 2022, revenues from Quest Diagnostics’ COVID-19 tests weighed in at barely half the size of the previous year’s haul—and the testmaker is now expecting 2023’s COVID-related earnings to shrink to an even smaller fraction. |
By Ben Adams After being crowned not just December’s biggest TV drug ad spender but also being No. 1 throughout last year, AbbVie’s Rinvoq started 2023 in its now accustomed top spot. |
By Ben Adams Are you a man with a plan or an “internal agonizer”? Those are the questions Endo is asking men in a new campaign aimed at getting people off the internet and into their doctor’s office to talk about a subject that Endo believes has remained taboo for long enough: Peyronie's disease. |
By Gabrielle Masson Cell therapy biotech Neurona has laid off a quarter of its staff, or 18 of 68 employees, a spokesperson confirmed with Fierce Biotech. |
By Andrea Park From the start, Bayer and Huma’s relationship has been a mutually beneficial one, with the Big Pharma contributing funding to Huma through its Leaps by Bayer VC arm and, in return, gaining access to the startup’s digital health technologies. |
By Kevin Dunleavy In five years under Kenji Yasukawa, Astellas had a successful rebound after revenues bottomed out in 2020. Now Astellas has tabbed chief strategy officer Naoki Okamura as its new CEO to "go on the aggressive." |
By Ben Adams The stress of watching your favorite team or athlete in a tough situation is a threat to your heart health, and German pharma Bayer, now official sponsor of Fans’ Hearts, is launching a new campaign to raise awareness of the relationship between the stress of sports fandom and cardiovascular health. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss what we can expect from the obesity market in 2023. We also recap the drugs approved last year. |
|
|---|
|
|
|
The global demand for biologics is projected to increase considerably by 2030, but the challenges, risks, and costs are also growing. For pharma companies looking to bring a new biologic to market, meeting clinical trial milestones can be difficult. To access important insights, download this executive summary now.
|
|
| Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
| WhitepaperThis paper explores the cost drivers behind gene therapies and how they are likely to evolve in the coming years. Sponsored by: Blue Matter |
| WhitepaperExploring the biology of G Protein-Coupled Receptors (GPCRs) and outlining a novel approach for developing therapeutics against previously undruggable GPCRs Sponsored by: Orion Biotechnology |
| WhitepaperLearn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| WhitepaperRCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
| Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
